Left Main Disease and a Ticagrelor Clock: How Long Can Surgery Actually Wait
A 57-year-old man with critical left main disease is three days into his ticagrelor washout when his angina recurs at rest. The guideline window that was supposed to make this decision simple is exactly what's now being weighed against the risk of waiting it out.
Miguel A., a 57-year-old man, runs a small fleet of delivery vans and was still making routes himself three days ago when crushing chest pain sent him to the emergency department, where catheterization found ninety percent stenosis of his left main coronary artery — anatomy his interventional cardiologist immediately flagged as a surgical rather than a stenting problem, given the territory a left main lesion supplies and the catastrophic consequences if it occludes completely. He was loaded with ticagrelor in the emergency department before the angiogram identified left main disease, standard practice for presumed ACS before the anatomy is known, and has been on it for three days since while the surgical team planned his operation. His platelet function assay this morning confirms he is still inhibited, so the residual drug effect is measured rather than inferred.
This morning, on maximal medical therapy — beta-blockade, nitrates, heparin infusion — he had a new episode of chest pain at rest, unprovoked by exertion, lasting several minutes before resolving with additional nitroglycerin. Recurrent rest angina in critical left main disease is not a symptom the team can wait out indefinitely; it is the anatomy itself signaling instability, and it carries more information about him specifically than any population-level default can. The guideline washout window his ticagrelor timing was originally tracking toward — shortened in the 2025 ACC/AHA update to three to five days rather than the older uniform five — puts him today at day three, which is to say at the earliest edge of an acceptable window rather than outside one. The tension is that the window's lower bound was itself arrived at by accepting some residual bleeding risk in exchange for earlier revascularization, and his own ischemia is now arguing that the same trade be made once more, a further step along the same curve, for a patient telling the team he may not have two more days to give.
Two days left on the washout clock, and his angina just recurred
I'd hold for the remaining window if at all possible. The 2025 ACC/AHA guideline shortened ticagrelor washout to three to five days for a real reason — even the shortened window exists because residual platelet inhibition meaningfully raises perioperative bleeding risk, and his platelet function assay confirms he's still inhibited today.
I hear that, but I don't think we can treat his rest angina this morning as background noise while we wait out a calendar window. Left main disease carries real, well-documented mortality risk the longer definitive revascularization is delayed, and recurrent rest angina on maximal medical therapy is exactly the signal that his anatomy may not be stable enough to give us the extra two days.
I'd also note the guideline window itself already represents an accepted tradeoff — it was shortened from five days precisely because the evidence supported accepting some residual bleeding risk in exchange for earlier revascularization. Proceeding two days into that window for a patient with actively recurring ischemia isn't a different kind of tradeoff from what the guideline itself already made, just a further point along the same curve.
That's a genuinely fair way to frame it, and I don't have a strong response to the idea that his own recurring symptoms are more informative than a population-level default window — you're right that the guideline number was never meant to override a patient actively showing you unstable anatomy.
I'll shift to preparing for surgery today rather than tomorrow. My ask is that we go in with a full high-dose antifibrinolytic protocol, platelets staged and ready rather than waited for, and the surgical team aware from the start that his hemostasis is going to need more active management than a patient who cleared the full washout.
Agreed: surgery proceeded that day rather than waiting out the remaining washout window, with high-dose antifibrinolytic therapy and staged platelet availability to actively manage the residual antiplatelet effect rather than avoid it through delay.
Not agreed as a general rule for future cases: how much weight recurrent angina on maximal medical therapy should carry against a guideline washout window as a matter of routine practice, versus being treated as an individual clinical judgment call each time it arises. Both voices treated today's decision as sound for this specific patient without committing to a fixed threshold for when symptoms alone should override the guideline default.